HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more
HUTCHMED (China) Limited (HMDCF) - Total Liabilities
Latest total liabilities as of December 2025: $501.83 Million USD
Based on the latest financial reports, HUTCHMED (China) Limited (HMDCF) has total liabilities worth $501.83 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HUTCHMED (China) Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how HUTCHMED (China) Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HUTCHMED (China) Limited Competitors by Total Liabilities
The table below lists competitors of HUTCHMED (China) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Poco Holding Co Ltd
SHE:300811
|
China | CN¥881.42 Million |
|
Inner Mongolia First Machinery Group Co Ltd
SHG:600967
|
China | CN¥9.40 Billion |
|
Hebei Yangyuan ZhiHui Beverage Co Ltd
SHG:603156
|
China | CN¥2.33 Billion |
|
Quaker Chemical Corporation
NYSE:KWR
|
USA | $1.45 Billion |
|
Linktel Technologies Co. Ltd. A
SHE:301205
|
China | CN¥1.17 Billion |
|
HEXPOL AB ser. B
LSE:0R7O
|
UK | Skr6.31 Billion |
|
Calumet Specialty Products Partners
NASDAQ:CLMT
|
USA | $3.18 Billion |
|
Manappuram Finance Limited
NSE:MANAPPURAM
|
India | ₹389.37 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down HUTCHMED (China) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED (China) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED (China) Limited (2005–2025)
The table below shows the annual total liabilities of HUTCHMED (China) Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $501.77 Million | -0.11% |
| 2024-12-31 | $502.34 Million | -6.35% |
| 2023-12-31 | $536.39 Million | +36.63% |
| 2022-12-31 | $392.57 Million | +17.84% |
| 2021-12-31 | $333.15 Million | +62.38% |
| 2020-12-31 | $205.17 Million | +34.79% |
| 2019-12-31 | $152.22 Million | +26.99% |
| 2018-12-31 | $119.86 Million | +6.11% |
| 2017-12-31 | $112.97 Million | -18.36% |
| 2016-12-31 | $138.38 Million | +8.55% |
| 2015-12-31 | $127.48 Million | +28.69% |
| 2014-12-31 | $99.06 Million | +22.55% |
| 2013-12-31 | $80.83 Million | -35.76% |
| 2012-12-31 | $125.82 Million | +7.13% |
| 2011-12-31 | $117.44 Million | +28.89% |
| 2010-12-31 | $91.12 Million | +73.71% |
| 2009-12-31 | $52.45 Million | +56.43% |
| 2008-12-31 | $33.53 Million | +11.93% |
| 2007-12-31 | $29.96 Million | +29.89% |
| 2006-12-31 | $23.06 Million | -74.63% |
| 2005-12-31 | $90.89 Million | -- |